Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate

Urology. 1995 Jul;46(1):2-13. doi: 10.1016/s0090-4295(99)80151-4.
No abstract available

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Humans
  • Life Expectancy
  • Male
  • Mass Screening / economics*
  • Medicare / economics*
  • Middle Aged
  • Neoplasm Staging
  • Prostate-Specific Antigen / analysis*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / therapy
  • Randomized Controlled Trials as Topic
  • Reimbursement Mechanisms
  • Survival Rate
  • United States / epidemiology

Substances

  • Prostate-Specific Antigen